课题基金 / 基金详情

CREST-2 Statistical and Data Coordinating Center - SDCC

CREST-2 Statistical and Data Coordinating Center - SDCC
CREST-2 统计和数据协调中心 - SDCC
批准号:
10298040
负责人:
George Howard
金额:
$158.73万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
未结题
起止时间:
2014-03-15 至 2026-08-31
关键词:
AbbreviationsAddressAdultAffectAgeAncillary StudyApplications GrantsAtherosclerosisBlindedBlood PressureCOVID-19COVID-19 pandemicCanadaCarotid ArteriesCarotid Atherosclerotic DiseaseCarotid EndarterectomyCarotid StenosisCarotid stentCessation of lifeClinicClinical TrialsClinical Trials Data Monitoring CommitteesCompanionsComputer AssistedCredentialingDataData Coordinating CenterDevicesDiabetes MellitusDoppler UltrasoundEndarterectomyEnrollmentEnsureEventFundingGoalsHyperlipidemiaHypertensionInformed ConsentInvestigationIpsilateralKnowledgeLDL Cholesterol LipoproteinsLife StyleLipoproteinsMarylandMedicalMedical RecordsModernizationMonitorMulticenter TrialsOperative Surgical ProceduresOutcomeOutcome StudyPatient RecruitmentsPatientsPeriodicityPrimary PreventionProceduresProprotein ConvertasesRadialRandomizedRandomized Clinical TrialsRecommendationReportingResearch DesignResearch PersonnelRiskRisk FactorsRisk ReductionSerine ProteaseSeveritiesSiteSpainStandardizationStatistical Data InterpretationStenosisStentsStrokeStroke preventionSubtilisinsSurgeonSymptomsTelephoneTelephone InterviewsUnited StatesUniversitiesWithdrawaladjudicateatherothrombosisbasecardiovascular risk factorcigarette smokingclinical applicationcognitive changecognitive functioncognitive testingcohortcompare effectivenessdata managementdesignexperiencefollow up assessmentfollow-uphypoperfusionimprovedinhibitor/antagonistmeetingsoperationpreventprimary endpointprimary outcomerandomized trialrecruitsafe patientsecondary endpointsecondary outcomesexstatistical centerstroke eventstroke risksuccesstherapeutic targettreatment armtreatment grouptrial comparingvascular risk factor

项目摘要

项目成果

George Howard的其他基金

相似基金

相关文献

中文摘要
翻译
这项应用的广泛和长期目标是促进由于颈动脉粥样硬化而有中风风险的患者对中风的一级预防。在美国,1%到2%的成年人有无症状的颈动脉粥样硬化性狭窄,超过50%的管腔狭窄。颈动脉狭窄通常通过动脉内膜切除术或支架置入术来治疗。在美国,每年大约有10万例颈动脉内膜切除术和4万例颈动脉支架手术。高达90%的这些手术是在没有症状的患者身上进行的。在20世纪80年代的S和90年代的S开始的评估血管重建术有效性的试验结果现在受到质疑,因为预防动脉粥样硬化和动脉血栓的药物治疗的改进,以及通过动脉内膜切除术和颈动脉支架植入术的血运重建术的同时改善。为了解决如何最好地治疗≥70%颈动脉分叉狭窄患者以预防中风的问题,我们目前正在完成CREST-2试验的第一个资金周期。CREST-2是一对平行随机多中心试验,主要目的是:1)比较强化医疗管理(IMM)和颈动脉内膜切除术加IMM(n=1240)的有效性;2)比较IMM和颈动脉支架置入术+IMM(n=1240)的有效性。主要终点是随机化后44天内的任何中风或死亡(围术期风险)加上同侧中风长达4年的随访期。一个重要的次要终点是认知功能,定期通过集中化、标准化的计算机辅助电话访谈进行评估。终点的评估方式对治疗分配是盲目的。IMM涉及对血管危险因素的集中管理,包括高血压、糖尿病、吸烟和高脂血症。主要的危险因素治疗目标是收缩压130毫米汞柱和低密度脂蛋白(LDL)胆固醇水平70毫克/分升。IMM还包括通过电话传递的定期生活方式指导。初步数据显示,IMM显著改善了治疗各分支的血管风险因素。截至2020年10月26日,美国、加拿大和西班牙共有70%(1734/2480)的所需患者被随机分配。所有手术都只能由有严格资质的外科医生和干预者进行。IMM和血运重建程序正在顺利实施。交叉和退出研究都在设计假设范围内,数据质量很高。CREST-2支持一项名为CREST-H(NCT03121209)的配套辅助研究,该研究测试了半球低灌注症患者血运重建的认知含义。我们要求提供支持,以完成招募,完成队列的随访(最后一名患者招募后2年),并报告研究结果。
英文摘要
The broad, long-term objective of this application is to advance primary prevention of stroke in patients at risk for stroke due to atherosclerosis of the carotid artery. One to two percent of adults in the U.S. have asymptomatic atherosclerotic stenosis of the carotid artery exceeding 50% luminal narrowing. Carotid stenosis is often managed either by endarterectomy or stenting. About 100,000 carotid endarterectomies and 40,000 carotid stenting procedures are done each year in the US. Up to 90% of these procedures are done on asymptomatic patients. The findings of trials assessing the efficacy of revascularization begun in the 1980’s and 1990’s that showed efficacy of revascularization are now in question because of improvements in medical therapy to prevent atherosclerosis and atherothrombosis and concurrent improvements in revascularization by endarterectomy and by carotid stenting. To address the question of how best to treat patients with ≥70% carotid bifurcation stenosis to prevent stroke, we are currently completing the first funding cycle for the CREST-2 trials. CREST-2 is a pair of parallel randomized, multicenter trials with the primary aims: 1) to compare the effectiveness of intensive medical management (IMM) vs. carotid endarterectomy plus IMM (n=1240), and 2) to compare the effectiveness of IMM vs. carotid stenting plus IMM (n=1240). The primary endpoint is a composite of any stroke or death within 44 days of randomization (periprocedural risk) plus ipsilateral stroke up to 4 years of follow-up. An important secondary endpoint is cognitive function, assessed periodically and by a centralized, standardized computer- aided telephone interview. Endpoints are assessed in a manner blinded to treatment assignment. IMM involves central management of vascular risk factors, including hypertension, diabetes mellitus, cigarette smoking and hyperlipidemia. Primary risk factor therapeutic targets are systolic blood pressure <130 mmHg and a low- density lipoprotein (LDL) cholesterol level of <70 mg/dL. IMM also includes telephone-delivered periodic lifestyle coaching. Preliminary data show that the IMM has significantly favorably improved vascular risk factors across treatment arms. As of October 26, 2020, a total of 70% (1734/2480) of the required patients have been randomized across the US, Canada, and Spain. All procedures are performed only by rigorously credentialed surgeons and interventionists. IMM and revascularization procedures are being successfully delivered. Cross- overs and withdrawal from the study are within design assumptions, and the quality of the data is high. CREST-2 supports a companion ancillary study known as CREST-H (NCT03121209) that tests the cognitive implications of revascularization in patients with hemispheric hypoperfusion. We are requesting support to complete recruitment, complete follow-up of the cohort (2-years after recruitment of last patient), and report study results.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Long-Term Observational Extension of Participants in the CREST-2 Randomized Clinical Trial
  • 批准号:
    10688017
  • 项目类别:
  • 资助金额:
    $75.35万
  • 财政年份:
    2021
  • 负责人:
    George Howard
  • 依托单位:
Long-Term Observational Extension of Participants in the CREST-2 Randomized Clinical Trial
  • 批准号:
    10294280
  • 项目类别:
  • 资助金额:
    $79.78万
  • 财政年份:
    2021
  • 负责人:
    George Howard
  • 依托单位:
Long-Term Observational Extension of Participants in the CREST-2 Randomized Clinical Trial
  • 批准号:
    10473895
  • 项目类别:
  • 资助金额:
    $76.07万
  • 财政年份:
    2021
  • 负责人:
    George Howard
  • 依托单位:
CREST-2 Statistical and Data Coordinating Center - SDCC
海外基金